OrbiMed’s Vor Biopharma VOR Stock Holding History

OrbiMed’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,590	Closed	-$445K	–	131
2022 Q3	$445K	Sell	5,590 -36,077	-87%	-$3.55M	0.01%	130
2022 Q2	$4.14M	Hold	41,667	–	–	0.08%	115
2022 Q1	$5.03M	Hold	41,667	–	–	0.08%	122
2021 Q4	$9.68M	Hold	41,667	–	–	0.12%	118
2021 Q3	$13.1M	Hold	41,667	–	–	0.14%	116
2021 Q2	$15.5M	Hold	41,667	–	–	0.16%	106
2021 Q1	$35.9M	Buy	+41,667	New	+$35.3M	0.34%	74

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

OrbiMed's VOR Position: Q4 2022 in Review

OrbiMed sold out of Vor Biopharma (VOR) in Q4 2022, closing a stake of 5,590 shares — an estimated $445K sold.

OrbiMed first reported a position in VOR in Q1 2021 and held it in 7 quarters. The position peaked at $35.9M in Q1 2021. 57 funds tracked by Wall St. Rank hold VOR as of Q4 2022.

OrbiMed reported no remaining Vor Biopharma position as of Q4 2022 after selling out during the quarter.
OrbiMed sold 5,590 Vor Biopharma shares in Q4 2022, an estimated $445K.
OrbiMed first reported a position in Vor Biopharma in Q1 2021 and held it in 7 quarters.
OrbiMed's Vor Biopharma position peaked at $35.9M in Q1 2021.
57 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2022.

Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.